Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Regeneron Pharmaceuticals, Inc.'s quarterly P/E stands at 24.6x, up 11.1% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has compressed 18.6% YoY to 14.8x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 18.84 | 24.55 | 10.32 | 10.25 | 21.81 | 22.09 | 22.77 | 21.17 | 38.38 | 21.55 | 23.14 | 21.13 | 28.65 |
| — | +11.1% | -54.7% | -51.6% | -43.2% | +2.5% | -1.6% | +0.2% | +34.0% | +25.4% | +56.7% | +6.8% | +41.3% | |
| P/S Ratio | 7.50 | 5.34 | 4.01 | 3.88 | 5.82 | 5.35 | 8.21 | 8.55 | 8.81 | 7.28 | 6.94 | 6.48 | 7.41 |
| — | -0.1% | -51.1% | -54.6% | -33.9% | -26.5% | +18.3% | +31.9% | +18.9% | +20.8% | +4.9% | +9.9% | +11.2% | |
| P/B Ratio | 2.72 | 2.65 | 1.95 | 1.90 | 2.40 | 2.76 | 4.17 | 4.30 | 4.10 | 3.85 | 3.75 | 3.41 | 3.99 |
| — | -3.9% | -53.3% | -55.7% | -41.5% | -28.2% | +11.2% | +26.2% | +3.0% | +6.0% | +3.4% | +4.6% | +0.5% | |
| P/FCF | 26.36 | — | 10.63 | 14.73 | 22.79 | 20.35 | 27.57 | 211.90 | 20.50 | 32.19 | 24.87 | 22.50 | 19.69 |
| — | — | -61.4% | -93.0% | +11.2% | -36.8% | +10.9% | +841.8% | +4.1% | +145.4% | -37.7% | -45.1% | +95.4% | |
| EV / EBITDA | 21.64 | 14.81 | 12.99 | 11.88 | 24.40 | 18.20 | 23.60 | 25.64 | 32.03 | 21.47 | 17.83 | 18.45 | 20.97 |
| — | -18.6% | -44.9% | -53.7% | -23.8% | -15.2% | +32.4% | +39.0% | +52.7% | +48.5% | +22.0% | +52.8% | +45.7% | |
| EV / EBIT | 24.75 | 15.82 | 8.48 | 9.48 | 19.19 | 20.98 | 20.38 | 18.58 | 38.67 | 21.43 | 20.79 | 18.74 | 26.39 |
| — | -24.6% | -58.4% | -49.0% | -50.4% | -2.1% | -2.0% | -0.9% | +46.6% | +40.5% | +64.9% | +9.8% | +44.8% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Regeneron Pharmaceuticals, Inc.'s operating margin was 25.6% in Q4 2025, down 1.7 pp QoQ and down 0.5 pp YoY. This marks the 3rd consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. Gross margin expanded 3.8% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.3% | 88.3% | 86.1% | 85.6% | 84.7% | 85.1% | 86.8% | 86.5% | 86.2% | 81.7% | 83.9% | 83.9% | 82.4% |
| — | +3.8% | -0.8% | -1.0% | -1.8% | +4.2% | +3.5% | +3.0% | +4.6% | -4.1% | -2.5% | -3.5% | -1.7% | |
| Operating Margin | 25.7% | 25.6% | 27.4% | 29.4% | 19.5% | 26.1% | 31.7% | 30.2% | 23.9% | 30.6% | 36.0% | 32.2% | 31.7% |
| — | -2.0% | -13.7% | -2.6% | -18.2% | -14.6% | -12.0% | -6.3% | -24.7% | -20.6% | -13.6% | -29.6% | -26.9% | |
| Net Margin | 31.4% | 21.7% | 38.9% | 37.9% | 26.7% | 24.2% | 36.0% | 40.4% | 23.0% | 33.8% | 30.0% | 30.7% | 25.9% |
| — | -10.2% | +7.9% | -6.2% | +16.3% | -28.3% | +20.2% | +31.7% | -11.2% | -3.7% | -33.1% | +2.8% | -21.2% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 14.9% | 2.7% | 4.8% | 4.7% | 2.8% | 3.1% | 4.7% | 5.2% | 2.7% | 4.6% | 4.1% | 4.1% | 3.5% |
| — | -13.2% | +2.9% | -9.6% | +1.0% | -31.4% | +13.1% | +27.3% | -23.1% | -16.0% | -34.0% | -2.9% | -29.6% | |
| ROA | 11.5% | 2.1% | 3.7% | 3.7% | 2.1% | 2.4% | 3.6% | 4.1% | 2.1% | 3.6% | 3.2% | 3.2% | 2.8% |
| — | -14.3% | +2.2% | -9.6% | +0.3% | -31.3% | +13.7% | +27.5% | -22.4% | -15.5% | -33.1% | +0.2% | -26.6% | |
| ROIC | 12.4% | 3.2% | 2.5% | 2.7% | 1.5% | 2.5% | 3.0% | 2.9% | 2.1% | 3.1% | 3.6% | 3.2% | 3.4% |
| — | +29.4% | -16.9% | -5.1% | -28.7% | -18.7% | -17.1% | -11.7% | -37.1% | -33.3% | -19.9% | -35.1% | -33.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Regeneron Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 2.4x, up from 2.3x last quarter — at a moderate level that warrants monitoring.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.11 |
| — | -6.0% | -5.2% | -5.7% | -8.1% | -11.5% | -15.0% | -14.8% | -12.9% | -12.7% | -13.9% | -13.8% | -15.2% | |
| Debt / EBITDA | 0.64 | 2.40 | 2.33 | 2.23 | 3.76 | 2.42 | 2.08 | 2.27 | 3.12 | 2.32 | 2.05 | 2.41 | 2.45 |
| — | -0.9% | +11.9% | -1.9% | +20.5% | +4.3% | +1.2% | -5.9% | +27.4% | +21.7% | +0.0% | +23.4% | +23.5% | |
| Current Ratio | 4.77 | 4.77 | 4.06 | 4.60 | 4.93 | 4.73 | 5.28 | 5.44 | 5.27 | 5.69 | 5.18 | 5.45 | 5.45 |
| — | +0.7% | -23.1% | -15.5% | -6.5% | -16.9% | +2.0% | -0.2% | -3.4% | +12.5% | -3.4% | +6.5% | +14.7% | |
| Quick Ratio | 4.22 | 4.22 | 3.33 | 3.72 | 4.03 | 3.95 | 4.46 | 4.62 | 4.51 | 4.94 | 4.47 | 4.64 | 4.67 |
| — | +6.8% | -25.3% | -19.4% | -10.6% | -20.0% | -0.2% | -0.5% | -3.4% | +15.0% | -1.2% | +5.8% | +14.1% | |
| Interest Coverage | 84.31 | 81.54 | 53.20 | 299.86 | 68.01 | 94.30 | 85.47 | 72.27 | 46.67 | 57.42 | 68.03 | 53.78 | 55.71 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonRegeneron Pharmaceuticals, Inc.'s current P/E is 18.8x. The average P/E over the last 4 quarters is 16.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Regeneron Pharmaceuticals, Inc.'s current operating margin is 25.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Regeneron Pharmaceuticals, Inc.'s business trajectory between earnings reports.